Racial differences in insulin-like growth factor binding protein-3 in men at increased risk of prostate cancer

Urology

Volumn 54, Issue 1, 1999, Pages 178-182

  Tricoli, James V ^a   Winter, Donna L ^a   Hanlon, Alexandra L ^a   Raysor, Susan L ^a   Watkins Bruner, Deborah ^a   Pinover, Wayne H ^a   Hanks, Gerald E ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; RELATIVE;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; INFANT, NEWBORN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 0033168795     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00129-6     Document Type: Article

References (29)

1. Cohen P, Peehl DM, and Rosenfeld RG: The IGF axis in the prostate. Horm Metab Res 26: 81-84, 1994.
2. Resnicoff M, Abraham D, Yutanawiboonchai W, et al: The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 55: 2463-2469, 1995.
3. Evan G, Wyllie A, Gilbert C, et al: Induction of apoptosis in fibroblasts by the c-myc protein. Cell 69: 119-125, 1992.
4. Pietrzkowski Z, Mulholland G, Cornelia L, et al: Inhibition of growth of prostate cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 53: 1102-1106, 1993.
5. Burfeind P, Chernicky CL, Rininsland F, et al: Antisense RNA to type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci 93: 7263-7268, 1996.
6. Cohen P, Peehl DM, Lamson G, et al: Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 73: 401-407, 1991.
7. Iwamura M, Sluss PM, Casamento JB, et al: Insulin-like growth factor 1: action and receptor characterization in human prostate cancer cell lines. Prostate 22: 243-252, 1993.
8. Cohen P, Peehl DM, Baker B, et al: Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab 79: 1410-1415, 1994.
9. Cohen P, Fielder PJ, Hasegawa Y, et al: Clinical aspects of insulin-like growth factor binding protein. Acta Endocrinol 124: 74-85, 1991.
10. Jones JI, and Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16: 3-34, 1995.
11. Rajah R, Valentinis B, and Cohen P: Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta 1 on programmed cell death through a p53 and IGF-independent mechanism. J Biol Chem 272: 12181-12188, 1997.
12. Leal SM, Liu Q, Huang SS, et al: The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor. J Biol Chem 272: 20572-20576, 1997.
13. Thrasher JB, Tennant MK, Twomey PA, et al: Immunohistochemical localization of insulin-like growth factor binding proteins 2 and 3 in prostate tissue: clinical correlations. J Urol 155: 999-1003, 1996.
14. Hampel OZ, Kattan MW, Yang G, et al: Quantitative immunohistochemical analysis of insulin-like growth factor-binding protein 3 in human prostatic adenocarcinoma: a prognostic study. J Urol 159: 2220-2225, 1998.
15. Kanety H, Madjar Y, Dagan Y, et al: Serum insulin-like growth factor-binding protein-2 (1GFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 77: 229-233, 1993.
16. Mantzoros CS, Tzonou A, Signorello LB, et al: Insulin-like growth factor 1 in relation to prostate cancer and benign hyperplasia. Br J Cancer Res 76: 1115-1118, 1997.
17. Chan JM, Stampfer MJ, Giovannucci E, et al: Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science 279: 563-566, 1998.
18. Wolk A, Mantzoros CS, Andersson S-O, et al: Insulin-like growth factor 1 and prostate cancer risk: a population-based case-control study. J Natl Cancer Inst 90: 911-915, 1998.
19. Watkins-Bruner D, Baffoe-Bonnie A, Miller S, et al: A prostate risk assessment program: a model for early detection of prostate cancer. Oncology 113: 325-334, 1999.
20. Morton R: Racial differences in adenocarcinoma of the prostate in North American men. Urology 44: 637-645, 1994.
21. Lehman EL: Nonparametrics: Statistical Methods Based on Ranks. San Francisco, Holden Day, 1975.
22. Snedecor GW, and Cochran WG: Statistical Methods, 7th ed. Ames, Iowa, Iowa State University Press, 1980.
23. Goodman-Gruen D, and Barrett-Conner E: Epidemiology of insulin-like growth factor-1 in elderly men and women. Am J Epidemiol 145: 970-976, 1997.
24. Ross R, Bernstein L, Judd H, et al: Serum testosterone levels in healthy black and white men. J Natl Cancer Inst 76: 45-48, 1986.
25. Wu AH, Whittemore AS, Kolonel LN, et al: Serum androgens and sex hormone-binding globulins in relation to life-style factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev 4: 735-741, 1995.
26. Ross RK, Bernstein L, Lobo RA, et al: 5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 339: 887-889, 1992.
27. Vijayakumar S, Quadri SF, Dong L, et al: Results of a study to correlate serum prostate specific antigen and reproductive hormone levels in patients with localized prostate cancer. J Natl Med Assoc 87: 813-819, 1995.
28. Ross RK, Pike MC, Coetzee GA, et al: Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 58: 4497-4505, 1998.
29. Eastman JA, May RA, Whatley T, et al: Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer. J Natl Cancer Inst 90: 756-760, 1998.